A-synuclein SPECT agent scopes out Parkinson’s

Kathy Mahdoubi | | Health Imaging | Molecular Imaging

A prospective Parkinson’s imaging agent taps into alpha-synuclein deposition in the brain, developers ICB International announced April 11.

The biotech company based in La Jolla, Calif., presented their findings earlier last month during the Keystone Symposium for Parkinson disease in Keystone, Co. The research showed evidence of preclinical binding of an alpha-synuclein agent beyond the blood brain barrier. ICBI is calling the agent an a-Syn-Smart Molecule (a-Syn-SM).

"These recent discoveries bring ICBI closer to developing diagnostics and disease modifying therapeutics for neurodegenerative disorders," said Ram Bhatt, PhD, the company’s founder. 

This is reportedly the first visualization of alpha-synuclein in a living brain using the agent. Alpha-synuclein is being touted as an ideal target for Parkinson’s disease due to the misfolding and aggregation of these proteins in nerve cells throughout the central nervous systems of people with the neurodegenerative disorder.

The presented study included live rodent models with Parkinson’s and health controls injected with Iodine-125 labeled a-Syn-SM imaged with SPECT. Alpha-synuclein binding was detected within an hour and continued to be present for eight days after injection of the agent. The molecule may also be used in investigational PET agents in the future.

The agent has the potential to perform better than other small molecule agents that don’t appear to have strong impact on the central nervous system and large molecule agents that are usually blocked by the blood brain barrier. Further studies are required to see the definitive value of this novel molecular imaging agent for Parkinson’s disease. 

Kathy Mahdoubi

Related Content

Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage
NorthStar opens facility to assist with development and distribution of vital radioisotopes
Lizard saliva could be key to spotting elusive pancreatic tumors

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.